Captrust Financial Advisors An2 Therapeutics, Inc. Transaction History
Captrust Financial Advisors
- $43.1 Billion
- Q2 2025
A detailed history of Captrust Financial Advisors transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 40,000 shares of ANTX stock, worth $49,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,000
Previous 10,000
300.0%
Holding current value
$49,200
Previous $13,000
223.08%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
39Shares Held
7.6MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.76 Million0.71% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.27 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY583KShares$716,8070.62% of portfolio
-
Stonepine Capital Management, LLC Bend, OR544KShares$669,7270.57% of portfolio
-
Landscape Capital Management, L.L.C.495KShares$609,3370.05% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $23.9M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...